{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.15","value":"0.69"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"}],"units":"Participants"}],"description":"Described via means and standard deviations in samples which have acquired resistance to lestaurtinib","dispersionType":"Standard Deviation","groups":[{"description":"Population Description: Eligible patients with MLL-R (rearranged). Considered Intermediate Risk (IR) if age \\>= 90 days at diagnosis and High Risk (HR) if age \\< 90 days at diagnosis.\n\nAsparaginase: Given IV, IM, or PO\n\nCyclophosphamide: Given IV\n\nCytarabine: Given IV or IT\n\nDaunorubicin Hydrochloride: Given IV\n\nDexamethasone: Given IV or PO\n\nEtoposide: Given IV\n\nFilgrastim: Given IV or SC\n\nLaboratory Biomarker Analysis: Correlative studies\n\nLestaurtinib: Given PO\n\nLeucovorin Calcium: Given IV\n\nMercaptopurine: Given PO\n\nMethotrexate: Given IV, IT, or PO\n\nMethylprednisolone: Given IV\n\nPegaspargase: Given IM\n\nPharmacological Study: Correlative studies\n\nPrednisone: Given PO\n\nTherapeutic Hydrocortisone: Given IT\n\nVincristine Sulfate: Given IV","id":"OG000","title":"Arm C (IR/HR MLL-R Chemotherapy and Lestaurtinib)"}],"paramType":"MEAN","populationDescription":"Arm C Dose Level 2 patients who relapsed and had data collected","reportingStatus":"POSTED","timeFrame":"At relapse (up to 3 years)","title":"Describe in Vitro Sensitivity as a Molecular Mechanism of Acquired Resistance to Lestaurtinib in Leukemic Blasts","type":"SECONDARY","unitOfMeasure":"Proportion of cells that are viable"}